Lambda Biologics
Search
Profile

The full name

email@vos.com

Solutions

Organoid Service

º Oncology

Patient-derived cancer organoid based drug evaluation service

The oncology drug efficacy evaluation platform is based on patient-derived organoids (PDOs).

This advanced platform enables the evaluation of oncology agents and immunotherapeutics by utilizing a co-culture system incorporating immune cells from the tumor microenvironment.

Next-Generation Anti-Cancer Drug Development & Efficacy Evaluation with Patient-Derived Organoids (PDOs)

High-Fidelity Preclinical Models

Oncology utilizes 3D patient-derived organoids (PDOs) cultured directly from tumor biopsies.

These models preserve the original tumor’s genetic and phenotypic characteristics, providing a more clinically relevant system than traditional 2D cell lines or animal models.

Extensive Organoid Biobanking

A comprehensive biobank of PDOs, derived from a wide range of cancer types, forms an expansive repository that supports robust screening efforts.

This resource enables the identification of drug candidates across diverse tumor profiles and informs strategic decision-making throughout the R&D pipeline.

Established Cancer Organoid
Available pre-clinical research
  • Donor-matched immune microenvironment
  • Various patient-derived organoid lineups
  • High-resolution data (HCS, FACS, NGS, scRNAseq, multiflex IHC)
  • Fully customized service
PSC-derived organoid
  • Basic clinical data
  • Drug sensitivity prediction
  • Patient follow-up data
  • Clinical bioinformatics (NGS, RNAseq, Spatial biology)

Enhance clinical predictive accuracy by developing advanced in vitro models that more accurately recapitulate the Tumor Microenvironment (TME)

Immune-Microenvironment with Cytotoxic T cells
Immune checkpoint determine whether cancer cells are killed after TCR-MHC binding
Establishment of an immune checkpoint blockade evaluation platform utilizing cancer organoids and autologous T cells

Cancer Organoid

Endometrial Cancer Organoid

Cancer Organoid

Endometrial Cancer Organoid

1784€+

Hepatocarcinoma Cancer Organoid

Cancer Organoid

Hepatocarcinoma Cancer Organoid

1784€+

Lung Cancer Organoid

Cancer Organoid

Lung Cancer Organoid

1784€+

Ovarian Cancer Organoid

Cancer Organoid

Ovarian Cancer Organoid

1784€+

Gastric Cancer Organoid

Cancer Organoid

Gastric Cancer Organoid

1784€+

Pancreatic Cancer Organoid

Cancer Organoid

Pancreatic Cancer Organoid

1784€+

Colorectal Cancer Organoid

Cancer Organoid

Colorectal Cancer Organoid

1784€+

Cholangiocarcinoma Organoid

Cancer Organoid

Cholangiocarcinoma Organoid

1784€+

Breast Cancer Organoid

Cancer Organoid

Breast Cancer Organoid

1784€+

Tumor Microenvironment

Cancer Associate Fibroblast (CAF)

Tumor Microenvironment

Cancer Associate Fibroblast (CAF)

Cytotoxic T cell

Tumor Microenvironment

Cytotoxic T cell

6003€+

Tumor-Infiltrating Lymphocyte

Tumor Microenvironment

Tumor-Infiltrating Lymphocyte

9057€+

Regulatory T cell

Tumor Microenvironment

Regulatory T cell

7500€+

Macrophage

Tumor Microenvironment

Macrophage

7500€+

Validation Complete for cancer organoid

  • Clinical information
  • Drug sensitivity test
  • Genetic mutation (WES analysis)
  • Specific cancer marker expression (Immunohistochemistry, Multiflex)
WES analysis in pancreatic cancer organoid
Drug sensitivity test in pancreatic cancer organoid

Connect with Us